PE20181515A1 - Polipeptidos biparatopicos que antagonizan la senalizacion wnt en celulas tumorales - Google Patents

Polipeptidos biparatopicos que antagonizan la senalizacion wnt en celulas tumorales

Info

Publication number
PE20181515A1
PE20181515A1 PE2018001063A PE2018001063A PE20181515A1 PE 20181515 A1 PE20181515 A1 PE 20181515A1 PE 2018001063 A PE2018001063 A PE 2018001063A PE 2018001063 A PE2018001063 A PE 2018001063A PE 20181515 A1 PE20181515 A1 PE 20181515A1
Authority
PE
Peru
Prior art keywords
wnt signaling
tumor cells
polypeptides
methods
biparatopic polypeptides
Prior art date
Application number
PE2018001063A
Other languages
English (en)
Spanish (es)
Inventor
Vittoria Zinzalla
Klaus-Peter Kuenkele
Marie-Ange Buyse
Karen Cromie
Stephanie Staelens
Beatrijs Strubbe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20181515A1 publication Critical patent/PE20181515A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2018001063A 2015-12-04 2016-12-02 Polipeptidos biparatopicos que antagonizan la senalizacion wnt en celulas tumorales PE20181515A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15197999 2015-12-04

Publications (1)

Publication Number Publication Date
PE20181515A1 true PE20181515A1 (es) 2018-09-21

Family

ID=54782606

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001063A PE20181515A1 (es) 2015-12-04 2016-12-02 Polipeptidos biparatopicos que antagonizan la senalizacion wnt en celulas tumorales

Country Status (32)

Country Link
US (2) US10597449B2 (enExample)
EP (2) EP3383425B1 (enExample)
JP (2) JP6728355B2 (enExample)
KR (1) KR102802241B1 (enExample)
CN (1) CN108289943B (enExample)
AR (1) AR106949A1 (enExample)
AU (1) AU2016363787B2 (enExample)
CL (1) CL2018001384A1 (enExample)
CO (1) CO2018005680A2 (enExample)
CY (1) CY1123454T1 (enExample)
DK (1) DK3383425T3 (enExample)
EA (1) EA201891331A1 (enExample)
ES (1) ES2821099T3 (enExample)
HR (1) HRP20201528T1 (enExample)
HU (1) HUE051777T2 (enExample)
IL (1) IL259119B (enExample)
LT (1) LT3383425T (enExample)
MA (2) MA54648A (enExample)
MX (1) MX380414B (enExample)
MY (1) MY200933A (enExample)
PE (1) PE20181515A1 (enExample)
PH (1) PH12018501155B1 (enExample)
PL (1) PL3383425T3 (enExample)
PT (1) PT3383425T (enExample)
RS (1) RS60823B1 (enExample)
SA (1) SA518391728B1 (enExample)
SG (1) SG11201804510PA (enExample)
SI (1) SI3383425T1 (enExample)
TW (1) TWI734719B (enExample)
UA (1) UA122079C2 (enExample)
WO (1) WO2017093478A1 (enExample)
ZA (1) ZA201802867B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014020233A2 (pt) 2012-02-28 2017-07-04 Irm Llc seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
PT3383425T (pt) * 2015-12-04 2020-10-07 Boehringer Ingelheim Int Polipéptidos biparatópicos que antagonizam a sinalização wnt em células tumorais
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US11033636B2 (en) * 2017-05-31 2021-06-15 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
WO2019108806A1 (en) * 2017-11-29 2019-06-06 Board Of Regents Of The University Of Texas System Compositions and methods for cancer therapy
CN118271444A (zh) 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
AU2019297522B2 (en) * 2018-07-05 2026-04-23 Surrozen Operating, Inc. Multi-specific Wnt surrogate molecules and uses thereof
WO2020080941A1 (en) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
KR20210099614A (ko) 2018-12-04 2021-08-12 노파르티스 아게 Cd3에 대한 결합 분자 및 이의 용도
US11578129B2 (en) 2019-03-29 2023-02-14 Boehringer Ingelheim International Gmbh LRP5 and PD-1 antagonist anticancer combination therapy
CA3130663A1 (en) 2019-03-29 2020-10-08 Boehringer Ingelheim International Gmbh Anticancer combination therapy
CN114040926B (zh) 2019-05-04 2025-07-29 印希比生物科学有限公司 结合cd123的多肽及其用途
EP3966338A1 (en) * 2019-05-08 2022-03-16 Inhibrx, Inc. Cd123 targeted immunotherapies
CN118909117A (zh) * 2019-08-14 2024-11-08 安托拉诊疗公司 与lrp6蛋白结合的抗体及使用方法
US20230183336A1 (en) * 2019-08-14 2023-06-15 Modmab Therapeutics Inc. Antibodies that bind to lrp5 proteins and methods of use
CN115023440B (zh) 2019-09-23 2025-09-12 特韦斯特生物科学公司 结合CD3ε的抗体
CN112794914B (zh) * 2019-11-14 2022-09-16 深圳华大生命科学研究院 一种基于噬菌体展示技术开发的alk纳米抗体及其应用
WO2021163490A1 (en) * 2020-02-14 2021-08-19 University Of Washington Targeted depletion of bacteria from mixed populations through programmable cell-cell adhesion
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
JPWO2023286854A1 (enExample) * 2021-07-16 2023-01-19
EP4646436A2 (en) * 2023-01-05 2025-11-12 Harpoon Therapeutics, Inc. Trop2 targeting trispecific protein for treatment of cancer
CN116375851B (zh) * 2023-03-03 2024-03-22 中国农业科学院兰州兽医研究所 一种抗禽流感病毒np蛋白的纳米抗体及其制备方法与应用
WO2025100520A1 (ja) 2023-11-10 2025-05-15 ペプチドリーム株式会社 ペプチド、ペプチド複合体、医薬組成物、細胞培養用組成物、及び医療用、診断用又は研究用に用いられる組成物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US6528054B1 (en) * 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
US7622267B2 (en) * 2006-05-30 2009-11-24 Van Andel Research Institute Low-density lipoprotein receptor 6 (LRP6) as a mammary stem cell marker and related methods
CN102537051B (zh) 2006-06-08 2014-11-26 日本精工株式会社 具有密封圈的冲压外圈滚针轴承及其制造方法
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CN100428934C (zh) 2006-09-07 2008-10-29 中国人民解放军第二军医大学 香豆素类化合物在制备诱导神经干细胞定向分化药物中的应用
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
JP2010511397A (ja) 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． 血清タンパク質と結合可能なペプチド
MX2010004761A (es) 2007-11-02 2010-05-19 Novartis Ag Moleculas y metodos para modular la proteina relacionada con el receptor de lipoproteina de baja densidad 6 (lrp6).
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
CA2721202A1 (en) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US8661423B2 (en) 2009-05-01 2014-02-25 Telcordia Technologies, Inc. Automated determination of quasi-identifiers using program analysis
US8276148B2 (en) 2009-12-04 2012-09-25 International Business Machines Corporation Continuous optimization of archive management scheduling by use of integrated content-resource analytic model
CA2777527C (en) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
EP2531523A1 (en) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
PH12012501744A1 (en) 2010-03-03 2021-08-09 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
KR101899835B1 (ko) 2010-03-24 2018-09-19 제넨테크, 인크. 항-ｌｒｐ６ 항체
MX2012012927A (es) * 2010-05-06 2013-05-01 Novartis Ag Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
CA2812785A1 (en) * 2010-10-20 2012-04-26 Genentech, Inc. Methods and compositions for modulating the wnt pathway
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) * 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
US8883735B2 (en) 2011-11-04 2014-11-11 Novartis Ag Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
JP5949270B2 (ja) 2012-07-24 2016-07-06 富士通株式会社 オーディオ復号装置、オーディオ復号方法、オーディオ復号用コンピュータプログラム
EP2888279A1 (en) * 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
PT3383425T (pt) * 2015-12-04 2020-10-07 Boehringer Ingelheim Int Polipéptidos biparatópicos que antagonizam a sinalização wnt em células tumorais

Also Published As

Publication number Publication date
ES2821099T3 (es) 2021-04-23
IL259119B (en) 2022-04-01
WO2017093478A1 (en) 2017-06-08
UA122079C2 (uk) 2020-09-10
MY200933A (en) 2024-01-24
PH12018501155B1 (en) 2024-06-28
HK1255725A1 (en) 2019-08-23
SA518391728B1 (ar) 2022-03-28
HRP20201528T1 (hr) 2020-12-11
TWI734719B (zh) 2021-08-01
CO2018005680A2 (es) 2018-06-12
CA3006235A1 (en) 2017-06-08
PT3383425T (pt) 2020-10-07
KR20180081825A (ko) 2018-07-17
PL3383425T3 (pl) 2021-01-11
AU2016363787A1 (en) 2018-05-17
DK3383425T3 (da) 2020-09-28
SG11201804510PA (en) 2018-06-28
MA43368A (fr) 2018-10-10
JP2019506841A (ja) 2019-03-14
HUE051777T2 (hu) 2021-03-29
ZA201802867B (en) 2026-03-25
US11952418B2 (en) 2024-04-09
AU2016363787B2 (en) 2023-02-02
US20170174762A1 (en) 2017-06-22
TW201731868A (zh) 2017-09-16
AR106949A1 (es) 2018-03-07
IL259119A (en) 2018-06-28
MA54648A (fr) 2021-11-10
CY1123454T1 (el) 2022-03-24
US10597449B2 (en) 2020-03-24
BR112018010537A2 (pt) 2018-11-13
PH12018501155A1 (en) 2019-01-28
EP3383425B1 (en) 2020-07-15
CL2018001384A1 (es) 2018-09-14
JP6728355B2 (ja) 2020-07-22
LT3383425T (lt) 2020-10-12
JP2020178701A (ja) 2020-11-05
EP3797790A1 (en) 2021-03-31
EP3383425A1 (en) 2018-10-10
CN108289943B (zh) 2023-06-20
EA201891331A1 (ru) 2018-12-28
MA43368B1 (fr) 2020-09-30
SI3383425T1 (sl) 2020-11-30
MX380414B (es) 2025-03-12
KR102802241B1 (ko) 2025-05-07
MX2018006760A (es) 2018-08-01
NZ742037A (en) 2025-07-25
CN108289943A (zh) 2018-07-17
RS60823B1 (sr) 2020-10-30
US20200199222A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
CO2018005680A2 (es) Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
CO2019012329A2 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
CY1122314T1 (el) Κυκλοπροπυλαμινες ως αναστολεις lsd1
CY1122415T1 (el) Κυκλοπροπυλαμινες ως lsd1 αναστολεις
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
ECSP17083788A (es) Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
CR20150255A (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
UY37018A (es) Inhibidores bicíclicos de pad4
CR20160542A (es) 1 H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS YPIRAZOLO[3,4-c]PlRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEINAS BET
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
UY33956A (es) Anticuerpo del factor antitisular humano y sus usos para tratar cáncer
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
MX373818B (es) Composiciones de apilimod y métodos para usar las mismas.
CO2019012475A2 (es) Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de ánimo
UY37980A (es) Compuestos novedosos para tratar enfermedades parasitarias
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
MX391474B (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
UA96814U (uk) Спосіб лікування онкологічних захворювань